Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms

Circulation. 2007 Jul 3;116(1):57-66. doi: 10.1161/CIRCULATIONAHA.106.666008. Epub 2007 Jun 18.

Abstract

Background: Proton pump inhibitors are used extensively for acid-related gastrointestinal diseases. Their effect on cardiac contractility has not been assessed directly.

Methods and results: Under physiological conditions (37 degrees C, pH 7.35, 1.25 mmol/L Ca2+), there was a dose-dependent decrease in contractile force in ventricular trabeculae isolated from end-stage failing human hearts superfused with pantoprazole. The concentration leading to 50% maximal response was 17.3+/-1.3 microg/mL. Similar observations were made in trabeculae from human atria, normal rabbit ventricles, and isolated rabbit ventricular myocytes. Real-time polymerase chain reaction demonstrated the expression of gastric H+/K+-adenosine triphosphatase in human and rabbit myocardium. However, measurements with BCECF-loaded rabbit trabeculae did not reveal any significant pantoprazole-dependent changes of pH(i). Ca2+ transients recorded from field-stimulated fluo 3-loaded myocytes (F/F0) were significantly depressed by 10.4+/-2.1% at 40 microg/mL. Intracellular Ca2+ fluxes were assessed in fura 2-loaded, voltage-clamped rabbit ventricular myocytes. Pantoprazole (40 microg/mL) caused an increase in diastolic [Ca2+]i by 33+/-12%, but peak systolic [Ca2+]i was unchanged, resulting in a decreased Ca2+ transient amplitude by 25+/-8%. The amplitude of the L-type Ca2+ current (I(Ca,L)) was reduced by 35+/-5%, and sarcoplasmic reticulum Ca2+ content was reduced by 18+/-6%. Measurements of oxalate-supported sarcoplasmic reticulum Ca2+ uptake in permeabilized cardiomyocytes indicated that pantoprazole decreased Ca2+ sensitivity (Kd) of sarcoplasmic reticulum Ca2+ adenosine triphosphatase: control, Kd=358+/-15 nmol/L; 40 microg/mL pantoprazole, Kd=395+/-12 nmol/L (P<0.05). Pantoprazole also acted on cardiac myofilaments to reduced Ca2+-activated force.

Conclusions: Pantoprazole depresses cardiac contractility in vitro by depression of Ca2+ signaling and myofilament activity. In view of the extensive use of this agent, the effects should be evaluated in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects
  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacology*
  • Actin Cytoskeleton / drug effects*
  • Aniline Compounds / analysis
  • Animals
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / pharmacology*
  • Calcium / metabolism
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / metabolism
  • Calcium Signaling / drug effects*
  • Depression, Chemical
  • Diastole
  • Female
  • Fluoresceins / analysis
  • Fluorescent Dyes / analysis
  • Heart Atria / drug effects
  • Heart Failure / physiopathology
  • Heart Ventricles / cytology
  • Heart Ventricles / drug effects
  • Humans
  • Hydrogen-Ion Concentration
  • In Vitro Techniques
  • Ion Transport / drug effects
  • Myocardial Contraction / drug effects*
  • Myocardium / enzymology
  • Myocytes, Cardiac / drug effects
  • Oxalates / pharmacology
  • Pantoprazole
  • Patch-Clamp Techniques
  • Polymerase Chain Reaction
  • Proton Pump Inhibitors*
  • Proton Pumps / analysis
  • Rabbits
  • Sarcoplasmic Reticulum / drug effects
  • Systole
  • Xanthenes / analysis

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Aniline Compounds
  • Anti-Ulcer Agents
  • Calcium Channels, L-Type
  • Fluoresceins
  • Fluorescent Dyes
  • Oxalates
  • Proton Pump Inhibitors
  • Proton Pumps
  • Xanthenes
  • Fluo-3
  • 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein
  • Pantoprazole
  • Calcium